Patents by Inventor Heinrich Rueeger

Heinrich Rueeger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic derivatives and their use in the treatment of neurological disorders
    Patent number: 10683287
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: June 16, 2020
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
    Publication number: 20200048236
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: April 9, 2019
    Publication date: February 13, 2020
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES AND THE USE THEREOF AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
    Publication number: 20190382399
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 19, 2019
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephen Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • Heterocyclic derivatives and their use in the treatment of neurological disorders
    Patent number: 10301296
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: May 28, 2019
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
    Publication number: 20190062319
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: June 27, 2018
    Publication date: February 28, 2019
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
    Patent number: 10202371
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: February 12, 2019
    Assignee: Novartis AG
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephen Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • Heterocyclic derivatives and their use in the treatment of neurological disorders
    Patent number: 10035794
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: July 31, 2018
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Imidazopyrrolidine derivatives and their use in the treatment of disease
    Patent number: 9890166
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: February 13, 2018
    Assignee: NOVARTIS AG
    Inventors: Jutta Blank, Guido Bold, Simona Cotesta, Vito Guagnano, Heinrich Rueeger, Andrea Vaupel
  • Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
    Publication number: 20170320864
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Application
    Filed: December 20, 2016
    Publication date: November 9, 2017
    Inventors: Sangamesh BADIGER, Murali CHEBROLU, Konstanze HURTH, Sebastien JACQUIER, Rainer Martin LUEOEND, Rainer MACHAUER, Heinrich RUEEGER, Marina TINTELNOT-BLOMLEY, Siem Jacob VEENSTRA, Markus VOEGTLE
  • Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
    Patent number: 9714249
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the pyrazolo-pyrrolidin-4-one derivatives, and their use as BET inhibitors for the treatment of conditions or diseases such as cancer. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: July 25, 2017
    Assignee: Novartis AG
    Inventors: Jutta Blank, Simona Cotesta, Vito Guagnano, Heinrich Rueeger
  • Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
    Patent number: 9624247
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (1) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: April 18, 2017
    Assignee: NOVARTIS AG
    Inventors: Jutta Blank, Guido Bold, Simona Cotesta, Vito Guagnano, Heinrich Rueeger
  • Heterocyclic derivatives and their use in the treatment of neurological disorders
    Patent number: 9550758
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: January 24, 2017
    Assignee: NOVARTIS AG
    Inventors: Sangamesh Badiger, Murali Chebrolu, Konstanze Hurth, Sebastien Jacquier, Rainer Martin Lueoend, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • Oxazolidin-2-one compounds and uses thereof
    Patent number: 9458177
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: October 4, 2016
    Assignee: NOVARTIS AG
    Inventors: Giorgio Caravatti, Robin Alec Fairhurst, Pascal Furet, Clive McCarthy, Heinrich Rueeger, Frank Hans Seiler, Frédéric Stauffer
  • OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES AND THE USE THEREOF AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
    Publication number: 20160168145
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 16, 2016
    Applicant: NOVARTIS AG
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephen Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20160108047
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 26, 2014
    Publication date: April 21, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Guido BOLD, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER, Andrea VAUPEL
  • PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20160102107
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 27, 2014
    Publication date: April 14, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Guido BOLD, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER
  • PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20160096843
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the pyrazolo-pyrrolidin-4-one derivatives, and their use as BET inhibitors for the treatment of conditions or diseases such as cancer. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 27, 2014
    Publication date: April 7, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Simona COTESTA, Vito GUAGNANO, Heinrich RUEEGER
  • PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20160095843
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 26, 2014
    Publication date: April 7, 2016
    Applicant: NOVARTIS AG
    Inventors: Jutta BLANK, Vincent BORDAS, Simona COTESTA, Vito NANO, Heinrich RUEEGER, Andrea VAUPEL
  • Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
    Patent number: 9296733
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: March 29, 2016
    Assignee: NOVARTIS AG
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephan Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • Oxazine derivatives and their use in the treatment of disease
    Patent number: 9284284
    Abstract: The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: March 15, 2016
    Assignee: NOVARTIS AG
    Inventors: Konstanze Hurth, Sebastien Jacquier, Rainer Machauer, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle